Carle Paul

发表

Ascomycins: promising agents for the treatment of inflammatory skin diseases

M. Graeber, C. Paul, A. Stuetz, 2000, Expert opinion on investigational drugs.

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

A. Gottlieb, L. Uhlmann, A. Kimball, 2023, The Lancet.

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

P. Emery, F. Nestle, J. Krueger, 2015, The Journal of dermatological treatment.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

G. Girolomoni, M. Gooderham, U. Mrowietz, 2015, The British journal of dermatology.

Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial

A. Gottlieb, K. Reich, U. Mrowietz, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

A 24‐week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis

E. Berardesca, J. Ortonne, C. Paul, 2013, The British journal of dermatology.

Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study

J. Ortonne, B. Sigurgeirsson, R. Schopf, 2012, The British journal of dermatology.

Oral pimecrolimus in the treatment of moderate to severe chronic plaque‐type psoriasis: a double‐blind, multicentre, randomized, dose‐finding trial

A. Gottlieb, J. Ortonne, V. Ho, 2005, The British journal of dermatology.

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

J. Erickson, M. Ohtsuki, K. Papp, 2018, The British journal of dermatology.

Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database

M. Lapeyre-Mestre, A. Sommet, J. Montastruc, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study

L. French, K. Reich, G. Micali, 2017, The British journal of dermatology.

Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

M. Lebwohl, K. Papp, K. Reich, 2023, The Lancet Rheumatology.

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

M. Lebwohl, K. Gordon, C. Paul, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

T. Wu, A. Blauvelt, R. Warren, 2020, The British journal of dermatology.

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

A. Gottlieb, K. Papp, K. Reich, 2016, The British journal of dermatology.

Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

K. Reich, J. Szepietowski, J. Szepietowski, 2020, The British journal of dermatology.

EMLA cream as a topical anesthetic for the repeated mechanical debridement of venous leg ulcers: a double-blind, placebo-controlled study.

B. Guillot, C. Lok, D. Bessis, 1999, Journal of the American Academy of Dermatology.

Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients

P. Payoux, P. Rochaix, R. Viraben, 2009, The British journal of dermatology.

Long‐term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis

W. Gulliver, M. Lahfa, C. Paul, 2004, The Journal of dermatological treatment.

Psoriasis: rationale for targeting interleukin‐17

G. Girolomoni, U. Mrowietz, C. Paul, 2012, The British journal of dermatology.

Imatinib mesylate in scleroderma‐associated diffuse skin fibrosis: a phase II multicentre randomized double‐blinded controlled trial

S. Lepreux, E. Hachulla, S. Prey, 2012, The British journal of dermatology.

Ciclosporin in psoriasis clinical practice: an international consensus statement

A. Finlay, L. Dubertret, V. Ho, 2004, The British journal of dermatology.

Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme

T. Luger, K. Papp, Y. Prost, 2004, The British journal of dermatology.

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

C. Griffiths, F. Cambazard, C. Paul, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids

V. Ho, S. Calvieri, D. Murrell, 2007, The British journal of dermatology.

Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin

A. Finlay, F. Rutten, P. Verboom, 2001, The British journal of dermatology.

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

C. Paul, C. Papavassilis, J. Lacour, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

A. Gottlieb, M. Lebwohl, K. Reich, 2020, The British journal of dermatology.

A randomized controlled evaluator‐blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis

S. Chevret, L. Dubertret, M. Lahfa, 2002, The British journal of dermatology.

Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1‐year multicentre, randomized study

Griffiths, V. Ho, C. Griffiths, 1999 .

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

P. Emery, F. Nestle, G. Girolomoni, 2015, The Journal of dermatological treatment.

Changes in interleukin‐17A, macrophage‐derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO‐ABLE study

R. Kaldate, C. Livideanu, A. Snel, 2018, The British journal of dermatology.

Gemcitabine treatment in cutaneous T‐cell lymphoma: a multicentre study of 23 cases

P. Morel, H. Bachelez, D. Chaoui, 2009, The British journal of dermatology.

Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial

C. Paul, C. Papavassilis, J. Nyirady, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.